Physician profile
Diane Chang
NPI 1588826168
$1,781.81
in general payments reported to CMS, 2019-2025
21 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.59 · 2020: $48.86 · 2021: $183 · 2022: $389 · 2023: $346 · 2024: $315 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $411.04 | 2021-2023 | Acthar |
| Alcon Vision LLC | $305.01 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $211.90 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $118.26 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $118.07 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $76.60 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $68.71 | 2022-2024 | Tecnis Simplicity |
| Dompe US, INC. | $58.38 | 2022-2025 | Oxervate |
| Biotissue Holdings INC. | $57.04 | 2024-2025 | |
| Amgen INC. | $56.95 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.60 | 2019 | |
| Kala Pharmaceuticals, INC. | $49.42 | 2021 | |
| Aerie Pharmaceuticals, INC. | $40.20 | 2021 | |
| Rayner Intraocular Lenses Limited | $27.97 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $25.84 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $22.29 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Glaukos Corporation | $17.60 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $15.92 | 2022 | |
| Shire North American Group INC | $14.43 | 2019 | |
| Allergan, INC. | $14.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.